FDA 483 - Sunbest Food LLC - April 19, 2011

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed three key deficiencies related to quality systems and manufacturing controls.

Observation 1 indicates that the firm failed to establish adequate procedures for the cleaning and maintenance of equipment. This suggests a potential risk of cross-contamination or product degradation due to improperly maintained machinery.

Observation 2 highlights that the firm did not adequately validate the manufacturing process for Drug X. Process validation is crucial to ensure that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. The lack of adequate validation raises concerns about the consistent quality and safety of Drug X.

Observation 3 states that the firm did not have proper controls in place to prevent contamination of Drug Y. This is a critical finding, as contamination can directly impact the safety, efficacy, and purity of the final drug product, potentially posing significant health risks to patients.

These observations collectively point to deficiencies in the facility's quality management system, specifically concerning equipment procedures, process validation, and contamination control for Drug X and Drug Y. The document does not specify the facility name, location, or the dates of the inspection.